Modulatory biomarkers such as proprotein convertase subtilisin/kexin type 9 (PCSK9), angiopoietin-like protein (ANGPTL), and fibroblast growth factors (FGFs) play a significant role in modulating the risk of hypothyroidism-associated hyperlipidemia [57]. This evidence concerns the gene PCSK9 and hypothyroidism.